In this retrospective cohort study emulating the CREDENCE and DAPA-CKD trials and based on multi-institutional routine care data from Taiwan, patients with T2D and CKD stages 1 to 3 and newly receiving SGLT2 inhibitors had a lower incidence of composite anemia outcomes compared with those newly receiving GLP-1 RAs. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.